Thursday, August 21, 2014

Google Wants You to Live 170 Years


Along the lines of self-driving cars and smart glasses, Google's newest venture promises to wow the tech scene. Only, it's not quite tech, at least in the traditional sense. The venture is called California Life Company, or Calico for short, and its goal is to extend human life by 20 to 100 years.

It sounds surreal, until consider that we already extended human life by 20 years over the past century. The average girl born today will live to be 100, a once outlying achievement.

Other research outlets have made relevant discoveries over the years, including worms that divide stem cells without aging and that resveratrol, found in red wine, seems to defend against diseases related to aging and could be manufactured as a more potent synthetic drug.

Meanwhile, companies such as Elixir Pharmaceuticals, Sirtris Pharma and Halcyon Molecular set out to extend human life, only to shut down (or be acquired, then shuttered by the buyer), many times running out of money before bringing a product to market.

Don't be quick to assume Google's involvement is strictly to benefit the common good, however. CEO Larry Page is pushing to spend on long term rather than incremental R&D. There's money to be made here. The regenerative medicine industry is valued at $1.6 billion, and anti-aging products are virtually resistant to economic cycles. Therapies available today may be expensive, untrustworthy and could produce horrific results.

But one thing is true: The quest to live just a bit longer is in demand.

Read more

Thursday, August 7, 2014

If the Body Is a Machine, Can It Be Maintained Indefinitely?

Excerpt from article

Metabolic processes drive the day-to-day business of living, but they also inevitably cause cellular damage. The body’s range of self-repair mechanisms don’t take care of everything. Eventually, a lifetime of accumulated damage causes the familiar signs of aging like “thinning skin, cloudy eyes, muscles sapped of strength, heart disease, and cognitive decline.”

De Grey is known for his research into engineered negligible senescence. Negligible senescence is a term used to describe certain animals that don’t display symptoms of aging. De Grey believes we can use biotechnology to engineer negligible senescence in humans, and he cofounded the SENS Research Foundation to lead the way.

SENS focuses on seven categories of universal damage that contribute to aging.

Read article